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Summary. Aim: We describe the safety profile of nifedipine
GITS as assessed from adverse events reported in the AC-
TION trial in which 7,665 patients with stable, symptomatic
coronary artery disease were randomly assigned nifedipine
GITS or placebo and followed for a mean of 4.9 years. Meth-
ods: All adverse events were coded using the COSTART cod-
ing dictionary. The incidence rate for each event was calcu-
lated as the number of patients with the event concerned
divided by the total time ‘at risk’. Hazard ratios comparing
nifedipine with placebo and their 95% confidence intervals
were obtained by Cox proportional-hazards analysis. Results:
As reported previously, nifedipine significantly reduced the
incidence of cardiovascular events and procedures [hazard
ratio (HR) 0.89, 95% confidence interval (CI) 0.83–0.95].
Apart from the known side effects of nifedipine, which in-
clude peripheral oedema, vasodilatation, hypotension, asthe-
nia, constipation, leg cramps, non-specific respiratory com-
plaints, impotence and polyuria, and which were reported
more frequently in patients assigned nifedipine, the inci-
dence rates of most other adverse events were similar. There
were no differences in the occurrence of gastrointestinal
haemorrhage, myocardial infarction and suicide. The rate of
occurrence of death or new cancer excluding non-melanoma
skin cancer for patients with no history of cancer at base-
line was 2.53/100 patient years for patients assigned nifedip-
ine and 2.37/100 patient years for patients assigned placebo
(HR 1.06, 95% CI 0.93–1.22). Conclusion: Overall nifedipine
GITS was well tolerated by patients with stable symptomatic
angina.
Key Words. randomised controlled trial, angina pectoris,
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Introduction
In the mid 1990s there was vigorous debate about the
safety of calcium channel antagonists in the treatment
of cardiovascular diseases [1–11]. A case-control study
had suggested an increased risk of myocardial infarction
in hypertensive patients treated with calcium channel
antagonists [12]. Further questions about safety were
raised in a meta-analysis of randomised, controlled trials
in patients with ischaemic heart disease [13], and in the
EPESE (Established Populations for Epidemiologic
Studies of the Elderly) cohort study of antihypertensive
medications in the elderly [14]. There was uncertainty
whether the observed cardiovascular adverse effects
were confined to short-acting formulations of calcium
channel antagonists, or were a drug-class action [15].
In addition claims were made concerning an increased
risk of cancer, major gastrointestinal haemorrhage, and
suicide [16–21].
More recently, several studies with calcium channel
antagonists have been reported mostly in patients with
hypertension or with acute coronary syndromes. The
findings refuted the earlier claims of harm [22–26].
However, data on the efficacy and safety of nifedipine,
especially of the long-acting formulation, in stable angina
was lacking. TIBET (Total Ischemic Burden European
Trial) [27] showed no difference between slow-release
nifedipine, atenolol and their combination for major
cardiovascular endpoints in patients with stable angina
while the withdrawal rate of study medication was
highest in the combination group [28]. As TIBET was
too small to assess effects on morbidity and mortality,
the need for a large-scale and long-term trial remained.
From the randomised, placebo-controlled ACTION
trial (A Coronary disease Trial Investigating Outcome
with Nifedipine GITS) in 7,665 patients with stable
symptomatic coronary disease followed for a mean of
4.9 years, we have reported the effects of long-acting
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nifedipine GITS (gastro-intestinal therapeutic system)
on clinical outcomes [29]. The conclusion was that the ad-
dition of nifedipine GITS to the conventional treatment
of angina pectoris was safe and survival free of a car-
diovascular event or a procedure was prolonged. As is
customary in drug trials, adverse events were recorded
using the International Conference on Harmonisation
(ICH) Good Clinical Practice (GCP) definitions. We
report here the general safety profile of nifedipine GITS
based on adverse events reported in the ACTION trial.
Methods
Design
The ACTION study was carried out in accordance with
the provisions of the Declaration of Helsinki, ICH GCP
requirements of the European Union and relevant lo-
cal laws and regulations. Its design, methods and main
results have been published previously [29, 30]. Briefly,
patients aged 35 years or older with stable symptomatic
angina pectoris requiring treatment were randomly as-
signed in equal proportions to either nifedipine GITS
or matching placebo in addition to their current treat-
ment. Apart from angina, patients had to have either
a history of MI, proven angiographic coronary artery
disease (CAD), or a positive exercise test or perfusion
defect. The left-ventricular ejection fraction had to be
at least 40%. Major exclusions were: clinically signifi-
cant heart failure, any major CV event or intervention
within the last three months, planned coronary angiog-
raphy or intervention, known intolerance to dihydropy-
ridines, clinically significant valvular or pulmonary dis-
ease, unstable insulin-dependent diabetes mellitus, any
gastro-intestinal condition that prohibited the use of
GITS tablets, any condition other than CAD that lim-
ited life expectancy, hypotension or uncontrolled hyper-
tension, and elevated creatinine or aminotransferase lev-
els. Women could only participate if there was no risk
of pregnancy. Detailed selection criteria and definitions
have been described elsewhere [30].
Initial treatment was with nifedipine GITS 30 mg
once daily, increasing to 60 mg once daily within six
weeks, or matching placebo. Physicians were encour-
aged to attempt risk factor modification and to treat
symptomatic angina with compatible medications.
Lipid-lowering treatment was either continued or
started at the same time as study medication according
to internationally accepted guidelines. The following
drugs could not be used in combination with study med-
ication: calcium channel antagonists (2-week washout
required before entry), cardiac glycosides (unless given
for supra-ventricular arrhythmias), other positive in-
otropic agents, class I or III anti-arrhythmics (other
than amiodarone or sotalol), cimetidine, anti-psychotic
and anti-epileptic drugs, rifampicin or rifampine.
Patients were seen in the out-patient clinic two
weeks, six weeks and six months after study medi-
cation was started, and from then onwards every six
months. Between visits, patients were contacted by tele-
phone. Reasons for stopping study medication earlier
than planned were coded in the Case Report Form and
included patient refusal, clinical reasons or contraindica-
tions, and the need to start concomitant treatment that
was incompatible with study medication.
Non-fasting blood tests were performed prior to
starting study medication for the following parameters:
creatinine, total creatine kinase (CK), aspartate amino-
transferase (ASAT), alanine aminotransferase (ALAT),
total bilirubin, alkaline phosphatase, sodium, potas-
sium, uric acid, glucose, total cholesterol, haemoglobin,
haematocrit and white blood cell count. Thereafter,
all tests except total cholesterol were repeated after
6 months, and after every two years. All tests in-
cluding total cholesterol were repeated at the end of
follow-up.
A 12-lead ECG was performed before starting study
medication, and thereafter every 6 months. For each
ECG the investigator recorded the ventricular rate
(bpm), PQ, PR, QRS and QT intervals in milliseconds
(ms) and ST-depression in millivolts (mV), and coded
rhythm, conduction, and wave morphology abnormali-
ties.
Adverse event reporting
All patients were followed from the first intake of study
medication onwards until death or the pre-defined end
of follow-up irrespective of withdrawal of study medica-
tion beforehand. The sponsor’s standard adverse event
report forms based on CIOMS (Council for International
Organizations of Medical Sciences) recommendations
were used to document adverse events. An adverse
event was defined as any undesirable experience that
occurred during the trial, whether or not considered re-
lated to study medication. This included new laboratory
test and ECG abnormalities considered clinically rele-
vant by the investigator. An adverse event which was
fatal, life threatening, disabling, resulted in or prolonged
hospitalisation, or concerned the occurrence of cancer
was considered as serious. Serious adverse events were
reported within 24 hours of the investigator’s awareness
on the sponsor’s standard two-page serious adverse
event report form. The serious adverse event form was
also used to report major diagnostic and intervention
procedures irrespective of their indication. Based on the
terms reported by the investigator, all adverse events
were coded using the COSTART (coding symbols for
thesaurus of adverse reaction terms) coding dictionary
[31].
In our analysis, incidence of new cancer is only con-
sidered in patients without a baseline history of cancer.
Pathological reports were obtained for all cases of new
cancer during follow-up. The composite of death and inci-
dence of any cancer is reported since patients may have
died with undiagnosed cancer. Cancers excluding non-
melanoma skin cancers are reported since the diagnosis
and ascertainment of skin cancer can be misleading. This
approach has been used in major trials, [32, 33] one of
which [33] was the trial upon which the power calcula-
tion for ACTION was based [30].
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Statistical methods
We used the SLAIN (slope adjusted for intercept)
method [34] to assess effects of nifedipine on the rate of
change of laboratory parameters and QT, QRS, PQ/PR
ECG intervals. The SLAIN analysis estimates the slope
and intercept for each patient, using the laboratory test
values measured at baseline and during follow-up as
dependent, and time as an independent variable. The
slopes are then correlated with study drug treatment
while adjusting for intercept.
We considered all adverse events reported as of the
first intake of study medication up to the end of follow-
up for inclusion in the present report. For each ad-
verse event, we calculated by assigned treatment the
incidence rate, taken as the number of patients with
the event concerned divided by the total time ‘at risk’.
For this purpose, we combined serious and non-serious
adverse events, and ignored if the patient was using
double-blind study medication at the time of the event
or not. Hazard ratios (HRs) comparing nifedipine with
placebo and their 95% confidence intervals (CIs) were
obtained by Cox proportional-hazards analysis using
treatment allocation as the only covariate. No adjust-
ment for multiple testing was made.
Given the large number of reported cardiovascular
and non-cardiovascular adverse events, we limited tabu-
lation of events to the total that were reported for each
COSTART body system. In addition, we grouped car-
diovascular COSTART codes referring to the same clin-
ical entity (see Appendix) and tabulated all cardiovas-
cular adverse events reported in ACTION for which
there was a statistically significant (95% CI of HR
does not include unity) difference between treatment
groups, or that are mentioned in the manufacturer’s core
data sheet for nifedipine GITS, or which occurred at
a rate of at least 0.5/100 patient-years. For the non-
cardiovascular events, we tabulated for each body sys-
tem class those events that occurred statistically sig-
nificantly more frequently in one treatment group than
in the other, or are mentioned in the core data sheet
for nifedipine GITS as an untoward experience occur-
ring in at least 1% of patients, or were malignant. In
addition, we tabulated gastrointestinal bleeding (after
combining events as indicated in the Appendix), de-
pression and suicide attempt because these diagnoses
have been suggested to be related to calcium channel
antagonists [23]. Finally, we tabulated all events diag-
nosed as malignant separately and irrespective of their
frequency.
Results
As reported elsewhere [29], ACTION was completed as
planned. Study medication was started in 7,665 patients
(3 825 nifedipine GITS, 3 840 placebo). Key characteris-
tics of the ACTION population are shown in Table 1.
Alkaline phosphatase showed an upward trend of
1.13 U/L per year of follow-up in patients allocated
nifedipine as opposed to 0.02 U/L per year in patients
assigned placebo (p = 0.006, SLAIN method). Biliru-
binaemia and hyperuricaemia were reported more fre-
quently in patients assigned placebo than patients as-
signed nifedipine (HR 0.35, 95% CI 0.14–0.90; and HR
0.66, 95% CI 0.48–0.91 respectively, c.f. Figure 3). There
were no differences between treatment groups for the
other laboratory tests performed.
There were no effects on the PQ, QRS and QT in-
tervals in electrocardiograms. Effects of nifedipine on
changes of heart rate and blood pressure have been pub-
lished [29].
The total number of reported adverse events for pa-
tients assigned nifedipine and to placebo was similar (41
014 nifedipine, 40 775 placebo), as was the number of pa-
tients who experienced at least one adverse event (96%
in both treatment groups). The percentage of patients
who experienced at least one serious adverse event was
similar in both treatment groups (58%) but in total fewer
serious adverse events were reported for patients as-
signed nifedipine (8 191 as opposed to 8 530 for placebo).
Study medication was withdrawn permanently two or
more days before death or the end of follow-up in 1 305
(34%) patients assigned nifedipine and in 1 179 (31%) pa-
tients assigned placebo. The most frequent reason for
stopping study medication was refusal to continue (11%
of patients assigned nifedipine vs. 10% of patients as-
signed placebo) or intolerable signs or symptoms that
could not be controlled by dose reduction (11% of pa-
tients assigned nifedipine vs. 5% of patients assigned
placebo, p < 0.001).
Figure 1 shows adverse events using the COSTART
body system classification. The incidence rates of ad-
verse events within each COSTART body system were
similar in both treatment groups except for body as
a whole, cardiovascular, musculoskeletal, respiratory
and urogenital. Cardiovascular events excluding pe-
ripheral oedema and respiratory events were signifi-
cantly more frequent in patients assigned placebo; while
body as a whole, cardiovascular events including pe-
ripheral oedema, musculoskeletal and urogenital events
were significantly more frequent in patients assigned
nifedipine.
Figure 2 shows a breakdown of adverse events
within the COSTART body system cardiovascular. As
expected, assignment to nifedipine was associated with
a significantly increased incidence of peripheral oedema,
hypotension and vasodilatation, and significantly re-
duced incidence of angina pectoris, hypertension, heart
failure, bradycardia, and pericardial effusion.
Figures 3 and 4 show the occurrence of selected
(c.f. statistical methods) events for each COSTART
body system. For the COSTART body system body
as a whole, asthenia and viral infection occurred more
frequently in the nifedipine group. There was no differ-
ence in the rate of reported suicide attempts between
the two treatment groups. For the COSTART body
system digestive, constipation was significantly more
frequent in patients assigned nifedipine whereas the
rate of diarrhoea was significantly less in patients
assigned nifedipine. There was no difference in the rate
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Fig. 1. Combined occurrence of adverse events by COSTART body system class. Note: Dot size indicating the hazard ratio corresponds to
the percentage of patients concerned <33% (smallest dot), 33–66% (medium size dot), >66% (largest size dot). SAE denotes serious adverse
event and CI confidence interval. ∗Number of patients with event per 100 patient-years at risk.
Fig. 2. Break-down of cardiovascular adverse events.Note: Dot size indicating the hazard ratio corresponds to the percentage of patients
with the event concerned <3% (smallest dot), 3–15% (medium-size dot), >15% (largest size dot). SAE denotes serious adverse event and CI
confidence interval. ∗Number of patients with event per 100 patient-years at risk.
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Table 1. Key baseline characteristics of ACTION patients and main results
Nifedipine
(n = 3825)
Placebo
(n = 3840)
Baseline characteristics
Mean age (years) (SD) 63.5 (9·3) 63.4 (9.3)
Male gender (%) 3041 (80) 3043 (79)
History of MI (%) 1974 (52) 1924 (50)
Angiographic CAD, no MI (%) 1222 (32) 1249 (33)
Positive exercise or perfusion test, no history
of MI and angiography never done (%)
616 (16) 646 (17)
Current NYHA class II–III (%) 1756 (46) 1776 (46)
Anginal attacks (%) 3544 (93) 3526 (92)
History of peripheral CV disease (%)a 494 (13) 491 (13)
Diabetes mellitus (%) 567 (15) 546 (14)
Risk factors:
Current smoker (%) 686 (18) 670 (17)
Total cholesterol ≥ 5.0 mmol/l (%) 2382 (62) 2433 (63)
Body mass index ≥ 30.0 (%) 849 (22) 895 (23)
BP 140/90 mm Hg or higher (%) 1975 (52) 2002 (52)
Any of the above (%) 3291 (86) 3362 (88)
Patients with event during follow-up:
Death from any cause (rateb) 310 (1.64) 291 (1.53)
HR 1.07, 95% CI 0.91–1.25
Primary endpoint for safetyc (rateb) 562 (3.08) 558 (3.05)
HR 1.01, 95% CI 0.90–1.14
Primary endpoint for efficacy d (rateb) 804 (4.60) 828 (4.75)
HR 0.97, 95% CI 0.88–1.07
Myocardial infarction (rateb) 267 (1.46) 257 (1.39)
HR 1.04, 95% CI 0.88–1.24
Refractory angina (rateb) 150 (0.81) 174 (0.94)
HR 0.86, 95% CI 0.69–1.07
New overt heart failure (rateb) 86 (0.46) 121 (0.65)
HR 0.71, 95% CI 0.54–0.94
Debilitating stroke (rateb) 77 (0.41) 99 (0.53)
HR 0.78, 95% CI 0.58–1.05
Any stroke or TIAe (rateb) 187 (1.01) 258 (1.40)
HR 0.72, 95% CI 0.60–0.87
Peripheral revascularisation (rateb) 146 (0.79) 118 (0.63)
HR 1.25, 95% CI 0.98–1.59
Coronary angiography (rateb) 895 (5.46) 1068 (6.69)
HR 0.82, 95% CI 0.75–0.90
Percutaneous coronary intervention (rateb) 385 (2.15) 417 (2.34)
HR 0.92, 95% CI 0.80–1.06
Coronary bypass surgery (rateb) 294 (1.62) 371 (2.06)
HR 0.79, 95% CI 0.68–0.92
Death, CV events or procedures (rateb) 1439 (9.32) 1583 (10.50)
HR 0.89, 95% CI 0.83–0.95
Note. SD denotes standard deviation, MI myocardial infarction, CAD coronary artery disease, NYHA New York Heart Association, CV cardiovascular, BP blood
pressure (cuff method), TIA transient ischemic attacks, HR hazard ratio, CI confidence interval.
aStroke, transient ischemic attacks or claudication.
bNumber of patients with (combined) event per 100 patient-years at risk.
cDeath of any cause, myocardial infarction or debilitating stroke.
dDeath of any cause, myocardial infarction, refractory angina, new overt heart failure, debilitating stroke or peripheral revascularisation.
eIncludes non-confirmed strokes diagnosed by investigators and transient ischemic attacks.
of gastrointestinal bleeding between the two treatment
groups. In the COSTART body system musculoskele-
tal, leg cramps occurred significantly more frequently
in patients assigned nifedipine. In the COSTART body
system nervous, dizziness was reported frequently
(5/100 patient-years) and with equal frequency in both
treatment groups. Depression, cerebral ischaemia,
amnesia, cerebral haemorrhage, and dysarthria were
all significantly less often reported in patients assigned
nifedipine. In the COSTART body system respiratory,
respiratory disorder and hyperventilation were more
frequently reported for patients assigned nifedipine
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Fig. 3. Break-down of adverse events by COSTART body system class.Note: Dot size indicating the hazard ratio corresponds to the
percentage of patients with the event concerned <3% (smallest dot), 3–15% (medium-size dot), >15% (largest size dot). SAE denotes serious
adverse event and CI confidence interval. ∗Number of patients with event per 100 patient-years at risk.
whilst coughing and apnoea occurred more frequently in
the placebo group. In the COSTART body system skin
and appendages, there were significant differences for
eczema in favour of placebo and sweating in favour of
nifedipine. Urinary tract infection, impotence, polyuria,
urinary tract disorder and testis disorder were associ-
ated with nifedipine, while vaginitis and gynaecomastia
were associated with placebo.
The numbers of patients in each treatment group for
whom the presence of any form of cancer was known at
entry into the trial were similar: 170 (4.4%) nifedipine,
186 (4.8%) placebo. The numbers of patients without
a baseline history of cancer who were diagnosed with
cancer during follow-up are shown in Figure 5. Death
or the development of any cancer in patients without a
baseline cancer history occurred in 502 and 454 patients
assigned nifedipine and placebo respectively. The cor-
responding event rates were 2.88/100 patient-years for
nifedipine and 2.58/100 patient-years for placebo (HR
1.11, 95% CI 0.98–1.26). Any type of cancer was reported
for 311 patients assigned nifedipine and 262 patients
assigned placebo. The excess of 49 cases of any type of
cancer (0.29 per 100 years of follow-up) in the nifedipine
group was attributable almost entirely to an excess of
cancer within the COSTART body systems skin and
appendages (24 excess cases) and urogenital (27 excess
cases) in patients assigned nifedipine. Basal/squamous
cell carcinoma occurred in 63 patients assigned nifedip-
ine and 43 patients assigned placebo. Five patients with
non-melanoma skin cancer died during the study. None
of these deaths were related to the skin cancer. Exclud-
ing non-melanoma skin cancer, death or cancer occurred
in 445 patients assigned nifedipine and 419 assigned
placebo corresponding to rates of 2.53/100 patient years
and 2.37/100 patient years (HR 1.06, 95% CI 0.93–1.22).
The occurrence of cancer in the urogenital system
was more marked in females than in males. The total
number of women who had any urogenital cancer was
25 among those assigned nifedipine and eight among
placebo. The corresponding event rates were 0.70 and
0.22 per 100 patient years respectively (HR 3.24, 95%
CI 1.46–7.17). Breast cancer was diagnosed in 15 female
patients assigned nifedipine and seven female patients
assigned placebo (0.42/100 patient years and 0.19/100
patient years for female patients allocated nifedipine
and placebo respectively, rate difference 0.23/100 pa-
tient years). Breast cancer was also diagnosed in two
male patients—one each in the nifedipine and placebo
treatment groups. In Figure 5, other urogenital can-
cers included endometrial cancer in five patients as-
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Fig. 4. Break-down of adverse events by COSTART body system class.Note: Dot size indicating the hazard ratio corresponds to the
percentage of patients with the event concerned <3% (smallest dot), 3–15% (medium-size dot), >15% (largest size dot). SAE denotes serious
adverse event and CI confidence interval. ∗Number of patients with event per 100 patient-years at risk.
signed nifedipine and one patient assigned placebo, ovar-
ian cancer in four patients assigned nifedipine and no
patient assigned placebo, and cervical cancer in one
patient assigned nifedipine and no patient assigned
placebo.
Discussion
In the 1990s there was much controversy concern-
ing the safety of calcium channel antagonists fo-
cussing on short acting preparations and clinical out-
comes relating to myocardial infarction, gastrointesti-
nal haemorrhage, suicide and cancer. The ACTION
study was a large and long randomised trial using the
long-acting preparation of the calcium channel antag-
onist nifedipine in patients with stable symptomatic
angina pectoris. Its main results are summarised in
Table 1.
ACTION provided an opportunity for a detailed ex-
amination of adverse events. For the present purpose we
have analysed the complete ACTION safety database,
but report only COSTART codeable adverse events con-
sidered relevant (c.f. statistical methods). It follows that
there were no differences between treatment groups for
events not mentioned. Screening the safety data base
for differences and selecting events for inclusion in the
present report involved multiple testing of statistical
significance. We emphasise that this has implications for
cumulative type I errors and increases the probability
of chance findings. The more conservative approach is
to adjust for multiple testing when calculating p-values
and confidence intervals. This increases the probability
that legitimately significant results will not be detected
because of a type II error. Hence, we have opted to use
unadjusted tests, and report hazard ratios with 95% con-
fidence intervals rather than p-values. As always, the
findings should be considered in relation to plausibility,
existing scientific knowledge, specificity and coherence.
Furthermore, in interpreting our findings it is impera-
tive to consider the width of the confidence intervals re-
ported. A wide confidence interval for a rare event in-
dicates that our data does not allow a definitive conclu-
sion even when the interval does not include unity for
the hazard ratio.
The present analysis corroborates our previously
published results. The finding that nifedipine reduced
the incidence of new overt heart failure as classi-
fied by the ACTION Critical Events Committee was
novel [29]. The latter was based on strict criteria. A
similar conclusion with respect to heart failure was
obtained based on adverse events as reported by in-
vestigators. In addition, nifedipine reduced the rate
of angina pectoris, hypertension, bradycardia, and
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Fig. 5. Occurrence of cancer among patients without cancer at baseline.Note: CI denotes confidence interval. ∗Number of patients with
event per 100 patient-years at risk. †Includes ovarian, endometrial and cervix carcinoma.
cerebral ischemia and haemorrhage. As expected,
peripheral oedema in the absence of heart failure was
more common with nifedipine. The MATH trial also
reported that peripheral oedema was among the most
common adverse events of nifedipine GITS, but that
the oedema was not associated with overall body fluid
retention [36].
The known side effects of nifedipine, including
peripheral oedema, vasodilatation, hypotension, asthe-
nia, constipation, leg cramps, non-specific respiratory
complaints, impotence and polyuria were reported
more frequently for patients assigned nifedipine (Fig-
ure 2). The incidence rates of most other reported
adverse events were similar. There was an increase
in the rate of viral infection and urinary tract infec-
tion in the nifedipine group but the rate difference
between the two groups was small (0.10/100 patient
years and 0.28/100 patient years for viral infection
and urinary tract infection respectively). There was
no increase in the occurrence of myocardial infarction
or suicide. Major bleeding is another alleged adverse
event with calcium channel antagonists. Current evi-
dence is contradictory, and data specific to nifedipine
is scarce [23]. The findings in ACTION show that
nifedipine GITS does not cause major gastrointestinal
haemorrhage.
Many different types of cardiovascular drugs, includ-
ing antihypertensives, statins and angiotension receptor
blockers have been reported to increase the risk of
cancer [37–39]. A recent review of current evidence con-
cluded that although there may be a weak association
of β-blockers and diuretics therapy with malignancy,
the management of hypertension following current
treatment guidelines can be continued with little fear of
any substantial risk of cancer [40]. Data about the risk
of cancer in calcium channel antagonists users are con-
troversial [23,40]. Observational studies suggested that
use of calcium channel antagonists could be associated
with increased risk of malignancy [16,17]. Three large
case-controlled studies showed no association [41–43].
In a recent cohort study, where detailed information on
the drug use was available and potential confounders
were well controlled, an increased risk of cancer was
reported with verapamil, but the risk was not associated
with diltiazem or nifedipine use [44].
In the present study the rate of death or any cancer
(including non-melanoma skin cancer) was slightly
higher but not statistically different between the two
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treatment groups. The data on particular cancers is
based on small numbers of cases and significant differ-
ences could represent chance findings. The imbalance
in cancer between the two groups is driven by non-
melanoma skin cancers, which are usually excluded from
evaluations [32,33], and by urogenital cancers in females.
The number of females in the nifedipine and placebo
groups were 784 and 797. The small number of women
limits the reliability of any statistical assessment.
The adverse and serious adverse events reported in
the ACTION trial demonstrate that nifedipine GITS is
a well tolerated drug for use in the treatment of angina
with clear clinical benefit on cardiovascular events and
the rate of procedures. The information reported allows
the physician to balance efficacy and safety, and pro-
vide robust information to patients on side-effects of the
drug.
Appendix
For combined clinical entities shown in Figures 2 and
3, the COSTART terms included are listed below
(COSTART code between brackets).
Bradycardia: bradycardia (02010150), sinus bradycardia
(02010500).
Tachycardia: tachycardia (02010570), supraventricu-
lar tachycardia (02010540), ventricular tachycardia
(02010630), nodal tachycardia (02010400).
Hypotension: hypotension (02030270), postural hypoten-
sion (02030470).
Heart failure: heart failure (02010310), congestive
heart failure (02010180), cardiomegaly (02010170),
left heart failure (02010340), cardiomyopathy
(02010175), venous pressure increased (02030730),
pulmonary oedema (09050120), lung disorder
(09050110) when preferred term contains con-
gestion or rales unless the investigator terms
contains sounds. Included are also the investiga-
tor terms fluid in lungs or worsening pulmonary
stasis.
Other electrocardiogram abnormality: electrocardio-
gram abnormal (02010260), ST depressed (02010510),
T inverted (02010560), QT interval prolonged
(02010480), ST elevated (02010520), T amplitude
decreased (02010550),
Conduction abnormalities: AV block complete
(02010100), AV block first degree (02010110), AV
block 2nd degree (02010120), AV block (02010130),
Adams stokes syndrome (02010010), heart block
(02010300), PR interval prolonged (02010450), bundle
branch block (02010160)
Premature complexes: ventricular arrhythmia
(02010590), ventricular extrasystoles (02010600),
extrasystoles (02010280), bigeminy (02010140),
ectopia cordis (02010250).
Cardiac arrest: heart arrest (02010290), ventricular fib-
rillation (02010610).
Atrial arrhythmia: atrial arrhythmia (02010060), atrial
flutter (02010080), atrial fibrillation (02010070),
nodal arrhythmia (02010390), arrhythmia (02010050),
supraventricular extrasystoles (02010530).
Angina pectoris: angina pectoris (02010030), myocardial
ischaemia (02030380), coronary occlusion (02010220),
coronary thrombosis (02010230).
Thrombophlebitis: thrombophlebitis (02030600),
phlebitis (02030450), deep thrombophlebitis
(02030200).
Peripheral vascular disorder: vascular disorder
(02030660), peripheral vascular disorder (02030440),
occlusion (02030400), carotid occlusion (02030080),
arteriosclerosis (02030040), peripheral gangrene
(02030430).
Gastrointestinal bleeding: gastrointestinal hem-
orrhage (03090100), melena (03090140), he-
matemesis (03090120), hemorrhagic gastri-
tis (03160050), stomach ulcer hemorrhage
(03160100), duodenal ulcer hemorrhage (03040010),
esophageal hemorrhage (03060030), hemorrhage
of colon (03030020), peptic ulcer hemorrhage
(03080010).
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